

- **Name:** Minsuk Kwon, M.D., Ph.D.
 - **Current Position & Affiliation:** Clinical assistant professor, Department of Hematology-Oncology, Ajou University School of Medicine, Gyeonggi-do, Korea.
 - **Country:** Republic of Korea
-

• Educational Background:

- 2004.3. – 2010.2.: M.D., College of Medicine, Chung-Ang University, Seoul, Korea
- 2012.3. – 2014.2.: M.S. Internal Medicine, College of Medicine, Chung-Ang University, Seoul, Korea
- 2015.3. – 2019.2.: Ph.D. Immunology, Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea
- 2019.3. – 2021.2.: Clinical fellow, Division of Hemato-oncology, Department of Internal Medicine, Samsung Medical Center

• Professional Experience:

- 2010.3. – 2011.2.: Internship, Chung-Ang University Hospital, Seoul, Korea
- 2011.3. – 2015.2.: Residency, Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea
- 2015.3. – 2019.2.: Teaching Assistant, Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea
- 2019.3. – 2021.2.: Clinical fellow, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Seoul, Korea
- 2021.3. – present: Clinical assistant professor, Department of Hematology-Oncology, Ajou University School of Medicine, Gyeonggi-do, Korea
- 2022.3. –: Assistant professor, Department of Hematology-Oncology, Ajou University School of Medicine, Gyeonggi-do, Korea

• Professional Organizations:

- The Korean Association of Internal Medicine
- The Korean Cancer Association
- The Korean Society of Hematology
- Korean Society of Medical Oncology
- The Korean Association of Immunologists

• Main Scientific Publications:

1. Kim, R., **Kwon, M.**, An, M., Kim, S.T., Smith, S.A., et.al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD1 therapy. **Annals of Oncology**. (2021). doi:10.1016/j.annonc.2021.10.009 (**co-first author**)
2. **Kwon M**, An M, Klempner SJ, Lee H, Kim KM, et al. Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer.

- Cancer Discov.* 2021;11(9) 2168-2185. **(first author)**
3. Hwang IG, **Kwon M**, Kim JW et al. Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study. *Cancers* 2021; 13 (2): 331. **(co-first author)**
 4. Eum HH, **Kwon M**, Ryu D, Jo A, Chung W, Kim N, et al. Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer. *Experimental & Molecular Medicine* 2020;52:1976-88. **(co-first author)**
 5. **Kwon M**, Hong JY, Kim ST, et al. Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer. *Pathol Res Pract.* 2020 Jun;216(6):152947 **(first author)**
 6. **Kwon M**, Kim CG, Lee H, Cho H, et al. PD-1 blockade reinvigorates bone marrow CD8+ T cells from patients with multiple myeloma in the presence of TGF- β inhibitors. *Clinical Cancer Res.* 2020;26;1644-55 **(first author)**
 7. **Kwon M**, Choi YJ, Sa M, Park S-H, Shin E-C. Two-Round Mixed Lymphocyte Reaction for Evaluation of the Functional Activities of Anti-PD-1 and Immunomodulators. *Immune Netw.* 2018;18(6). **(first author)**
 8. Park J, **Kwon M**, Shin EC. Immune checkpoint inhibitors for cancer treatment. *Arch Pharm Res.* 2016;39(11):1577-1587. **(co-first author)**
 9. H.M. Shin, G. Kim, S. Kim, J.H. Sim, J. Choi, M. Kim, **M. Kwon**, S.-K. Ye, D.-S. Lee, S.W. Cho, S.T. Kim, J. Lee, H.-R. Kim, Chromatin accessibility of circulating CD8+ T cells predicts treatment response to PD-1 blockade in patients with gastric cancer, *Nature Communications*, 12 (2021).
 10. Yang, J., Moon, S., **Kwon, M.**, Huh, K. & Jung, C.W. A case of tuberculosis meningitis after allogeneic hematopoietic stem cell transplantation for relapsed Acute Myeloid Leukemia. *Transplant Infectious Disease*, e13482.
 11. Son SM, Woo CG, Kim DH, Yun HY, Kim H, Kim HK, Yang Y, Kwon J, **Kwon M**, Kim TY, Kim HD, Koh JY, Park SH, Shin EC, Han HS. Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients. *Sci Rep.* 2020 Aug 31;10(1):14293.
 12. Hur JY, Kim J-Y, Ahn JS, Im Y-H, Lee J, **Kwon M**, Park YH. Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience. *Cancers* (Basel). 2020;12(5):1306.
 13. S. Byeon, H. Kim, J. Kim, **M. Kwon**, J.Y. Hur, H.G. Jeon, S.S. Jeon, H.M. Lee, S.H. Park, Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study, *Investig Clin Urol* 61 (2020) 588-593.
 14. Park J, **Kwon M**, Kim KH et al. Immune Checkpoint Inhibitor-Induced Reinvigoration of Tumor-Infiltrating CD8+ T Cells is Determined by Their Differentiation Status in Glioblastoma. *Clinical Cancer Res.* 2019;25(8):2549-2559
 15. Kim CG, Jang M, Kim Y, Leem G, Kim KH, Lee H, Kim T-S, Choi SJ, Kim H-D, Han JW, **Kwon M**, Kim JH, Lee AJ, Nam SK, Bae S-J, et al. VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. *Science Immunology.* 2019;4(41):eaay0555.
 16. Park SE, Choi CW, **Kwon M**, Tae JH, Kim HJ. Spontaneous tumour lysis syndrome with follicular lymphoma. *Br J Hosp Med (Lond).* 2015;76(3):172-173.
 17. Shin HY, Choe JW, **Kwon M**, et al. Acute eosinophilic pneumonia leading to acute respiratory failure in a current systemic corticosteroid user. *Allergy Asthma Immunol Res.* 2013;5(4):242-244.
 18. Jung JW, **Kwon M**, Choi JC, et al. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. *Yonsei Med J.* 2013;54(5):1293-1296.